Real-world results from the EROS study show that early initiation of budesonide/glycopyrrone/formoterol fumarate treatment is associated with a lower risk of future exacerbations in COPD patients.
AstraZeneca presents the results of the EROS retrospective study, which associated treatment initiation with a triple fixed-dose combination of budesonide/glycopyrrone/formoterol fumarate within 30 days in patients with moderate or severe exacerbation of Chronic Obstructive Pulmonary Disease (COPD). decrease … + read more
SEMERGEN shares an updated manual for agile intervention in COPD
The document presents a simple and practical approach to the 8 thematic areas most relevant to COPD. + read more
The new results support early intervention with Trixeo for the treatment of COPD
Real-world results from the EROS study show that early initiation of budesonide/glycopyrrone/formoterol fumarate treatment is associated with a lower risk of future exacerbations in COPD patients. + read more
COPD patients are 61% more likely to die with an older hand
Patients with chronic obstructive pulmonary disease (COPD) who undergo major surgery are 61% more likely to die in the year after the operation. + read more
I ask COPD patients for the permanent elimination of tris seen therapy
In a statement, patients with COPD defended what appeared to be “an official obstacle that deprived the most vulnerable people of receiving the best care, even generating equity between the borders”. + read more
Internal medicine accounts for more than half of COPD exacerbations
The most common profile of a patient with COPD in internal medicine is male, elderly, smoker and with various comorbidities and polypharmacy. + read more
Keys to the 7th edition of the ARC on COPD
The purpose of conferences is to keep COPD closer to those doctors who care for patients with this pathology on a daily basis. + read more
